24-10-07 IntelGenx Technologies Corp. Announces Board Resignations CI
24-10-07 IntelGenx Technologies Corp. Announces Resignation of Andre Godin as Chief Financial Officer CI
24-10-07 IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer CI
24-10-01 ATAI Life Sciences AG completed the acquisition of the Assets of IntelGenx Technologies Corp. CI
24-07-19 IntelGenx Technologies Says Deadline Expires on Sale and Investment Solicitation Process MT
24-07-19 IntelGenx Technologies Brief: Providing Update on Prior Announced Sale, Investment Solicitation Process MT
24-07-03 IntelGenx Details Preliminary Efficacy Results for Montelukast VersaFilm Clinical Trial in Patients with Alzheimer's Disease MT
24-07-03 IntelGenx Brief: Says Obtained Preliminary Efficacy Results for the 'BUENA' Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease MT
24-06-11 IntelGenx Reports Launch of Sale and Investment Solicitation Process MT
24-05-28 IntelGenx Brief: Says Obtained Court-Approval of a Sale and Investment Solicitation Process; Had Recently Initiated Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives MT
24-05-27 ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp.. CI
24-05-21 IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives MT
24-05-17 IntelGenx Brief: Initiating Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives MT
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+1.70%+23.42%+74.20% 48.77B
-1.61%-0.29%+51.58%+118.38% 40.67B
-1.16%+0.37%+15.87%+86.01% 12.27B
-0.72%+0.72%-9.97%+14.04% 12.11B
+0.57%+1.73%+31.59%+153.11% 9.28B
-2.44%-3.83%+23.10%+43.23% 7.55B
-0.42%+0.89%+28.21%+223.05% 7.35B
-0.62%-0.84%+44.70%-11.26% 7.3B
-0.13%-0.16%-40.47%+15.85% 5.25B
Average -0.71%+1.04%+18.67%+79.62% 16.73B
Weighted average by Cap. -0.68%+1.25%+27.25%+86.65%
Logo IntelGenx Technologies Corp.
IntelGenx Technologies Corp. is a drug delivery company focused on the development and manufacturing of pharmaceutical films. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for pharmaceutical products that address unmet medical needs. Its VersaFilm is a drug delivery platform technology that enables the development of oral thin films. Its VetaFilm platform technology is designed for the application in companion animals. Its transdermal VevaDerm is a fully integrated solution provider for drug-in-adhesive transdermal products. Its product pipeline offers benefits to patients and physicians for many therapeutic conditions. It provides pharmaceutical services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.
Employees
-